IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re appli	cation of:)
	GRUBER et al)
Filed:	HEREWITH)
For:	ANTITHROMBOTIC T	THROMBIN VARIANTS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant hereby voluntarily discloses the reference listed on the attached Form PTO-1449 to the Assistant Commissioner for Patents. References (A-AA) were cited in a prior application relied upon by the above-identified application for an earlier filing date. The prior application relied upon is Application Serial No. 10/165,442, filed on June 7, 2002. It is specified in 37 CFR 1.98(d) that a "copy of any patent, publication or other information listed in an information disclosure statement is not required to be provided if it was previously cited by or submitted to the Office in a prior application, provided the prior application is properly identified in the statement and relied upon for an earlier filing date under 35 USC 120." Therefore please review the parent case for references (A-AA).

Applicant further reserves the right to establish the patentability of the claimed invention over any of the listed information should they be applied as references, and/or to prove that some of the cited information may not be prior art, and/or to prove that some of the cited information may not be enabling for the teachings they purport to offer. This statement further should not be construed as the representation that an exhaustive search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely

on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of the information, and to form independent opinions as to their significance.

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to account no. 09-0528.

Date: /0/3//2003

David J. Hayzer, Ph.D., J.I

Attorney for Applicant Registration No. 43,329

Womble Carlyle Sandridge & Rice, PLLC

P.O. Box 7037

Atlanta, GA 30357-0037

(404) 872-7000 (Telephone)

(404) 870-2413 (Facsimile)

Customer ID No.: 26158

Docket No.: **E056 1071.1**

Form PTO-1449 INFORMATION DISCLOSURE CITATION				E CITATION	E056 Appli	ney Docket 1071.1 icants:	No. Ser	ial No.				
						Filing	BER et al g Date: D HEREWI		Group Art Unit			
				U.S.	PATENT DOC	UMENT	S	<u> </u>		-		
Examiner Initials	Item	1	cument mber	Date	Nam	ie	Class	Subclass	Filing If Appro			
			Tr.	ODEI	 GN PATENT DO		NITC					
		Dog	cument	Date	Coun		Class	Subclass	Transl	ation		
		Number			004111		Ciuss	Buociass				
 									Yes	No		
	لــــــــــــــــــــــــــــــــــــ	OT]	HER DOCUM	ENTS	(Including Author	Title, Da	te. Pertinent I	Pages, etc.)		L		
		A	Arosio, et al M	lutation (of W215 Compromis	es Thrombi	in Cleavage of		but Not o	of		
	_	В	+		ochemistry 39, 8095- and Safety of Recom		<u> </u>	Protein C. fo.	r Sovere !	Sonsis		
			N. Engl. J. Me	d. 344, 6	599-709 (2001)							
		C Bonniec, et al Glu-192 → Gln substitution in thrombin mimics the catalytic switch thrombomodulin - Proc. Natl. Acad. Sci. 88, 7371-7375 (1991)							h induced	l by		
		D	Bouton, et al Role of the thrombin insertion loop 144-155, Study of thrombin mul K154E and a thrombin-based synthetic peptide - Eur. J. Biochem. 229, 526-532 (1)						tations W148G, 995)			
		Е	Cantwell & Di Cera - Rational Design of a Potent Anticoagula Chemistry 275, 39827-39830 (2000)					ant Thrombin - Journal of Biological				
F Di Cera - Anticoagulant Thrombins - Trends in						in Cardiova	n Cardiovascular Medicine 8, 340-350 (1998)					
i		G	Gibbs, et al Co 413-416 (1995)	nversion	n of thrombin into an	in into an anticoagulant by protein engineering – Nature 378,						
	H Gresele, et al Activated Human Protein C Prevents Thrombin-induced Thromboembolism Mice - Journal for Clinical Investigation 101, 667-676 (1998) I Gruber, et al The Thrombin Mutant W215A/E217A Shows Safe and Potent Anticoagulant Antithrombotic Effects in Vivo - Journal of Biological Chemistry 277, 27581-27584 (2002)								mbolism i	in		
									agulant a 4 (2002)	ınd		
		J	Gruber, et al <i>L</i> 2340-2348 (1992		etection of Activated I	Protein C i	n Blood from H	- Iuman Subje	ects – Blo	od 79,		
		K	C in a Primate Model - Blood 73, 639-642 (1989)									
		L										
		M	Hanson, et al Antithrombotic Effects of Thrombin-induced Activation of Endogenous Protein C in Primates – Journal for Clinical Investigation 92, 2003-2012 (1993)									
* EXAMI through cita applicant.	NER:	Init f not	ial if citation cons in conformance a	idered, v	whether or not citatio onsidered. Include co	n is in conf	formance with l	MPEP § 609 communica). Draw l	ine e		
EXAMINE	R'S S	IGN.	ATURE:		DATE	CONSIDE	RED:					

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Form PTO-1449 INFORMATION DISCLOSURE CITATION					• 1 4	E056	Attorney Docket No. E056 1071.1 Applicants: GRUBER et al			No. Serial No.		
					CITATION	1						
(Use several sheets if necessary)				iry)	Filing FILE		WITH Gro		oup Art Unit			
				U.S.	PATENT DOC	UMENT	S	_			-	
Examiner Initials	Item	n Document Number		Date	Na	ne		Class	Subclass		Filing Date If Appropria	
				OPFIC	GN PATENT D	OCUME	NTC	l 				· .
		Doo		Date	 				Subclass		Translatio	
		Document Number		Date Cour		iti y			Suociass			711
						Yes N					lo	
				<u> </u>	, , , , , , , , , , , , , , , , , , ,		•		١.,			
		OTI		•	(Including Autho							
		N	Harker, et al IIV-41-IV-55 (19	-	ntal Arterial Throm	bosis in No	nhuma	n Primat	es - (Circulat	tion 83,	
 		0			dulin is Present in I	Human Plas	sma an	d Urine -	- Jou	mal for	Clinical	
<u> </u>		P	Investigation 76 Kogan, et al F		Activator from the	Venom of A	agkistr	odon blo	mhoj	ffi ussu	riensis Retar	d
			Thrombus Form (1993)	ation in i	he Arterio-Venous	Shunt in Ra	ts - Th	rombosis	Res	earch 7	0, 385-393	
		Q	Leung, et al D		on of Thrombin's Star Medicine 10, 89		eractio	ns Using	Site-	Direct	ed Mutagene	si
		R	- Trends in Cardiovascular Medicine 10, 89-92 (2000) Marder, et al Plasmin Induces Local Thrombolysis without Causing Hermorrhage: A Comparison with Tissue Plasminogen Activator in the Rabbit - Thrombosis Haemostasis 86,									_
	·		745 (2001)									
		S			nctional Protein C , 253-264 (1986)	Assay Usin	g Prot	ac, A No	vel Pi	rotein (C Activator -	
		T	McBane, et al	Antithro	mbotic Action of Ei						l with a Later	nt
Porcine Thrombin Preparation – Thrombosis Haemostasis 74, 879-885 (199. U Richardson, et al Enhancing protein C interaction with thrombin results in a												
<u> </u>		V	 		60, 261-264 (1992) tesis of Thrombin S			tas Inhihi	tion	hu Cann	ing Uangrin	
		•			nbin III - The Journ							
		W Takahashi, et al Soluble Thrombomodulin Purified from Human Urine Exhibits a Potent Anticoagulant Effect In Vitro and In Vivo - Thrombosis Haemostasis 73, 805-811 (1995)										
		X	Taylor, et al Protein C Prevents the Coagulopathic and Lethal Effects of Escherichia coli Infusion in the Baboon – Journal for Clinical Investigation 79, 918-925 (1987)									
		Y	Tsiang, et al Protein Engineering Thrombin for Optimal Specificity and Potency of Anticoagulant Activity in Vivo - Biochemistry 35, 16449-16457 (1996)									
		Z	Vindigni, et al Release of Fibrinopeptides by the Slow and Fast Forms of Thrombin - Biochemistry 35, 4417-4426 (1996)									
		AA	Wu, et al Sing binding activitie	le amino s of hum	acid substitutions an thrombin - Proc.	<i>lissociate fi</i> Natl. Acad	brinog . Sci. 8	en-clottir 8, 6775-	ig an 6779	d thron (1991)	nbomodulin-	
* EXAMI nrough cita pplicant.	NER: ition if	Init not	ial if citation con in conformance a	sidered, v nd not co	whether or not citationsidered. Include	on is in con	formai	nce with with next	MPE com	P § 609 munica	9. Draw line	
XAMINE	R'S S	IGN	ATURE:		DAT	CONSIDI	ERED:					